Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

Abstract Background Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-individual pharmacokinetic (PK) variability of erlotinib may impact treatment outcome and/or toxicity. Recent in vivo s...

Full description

Bibliographic Details
Main Authors: Dorra Amor, Sébastien Goutal, Solène Marie, Fabien Caillé, Martin Bauer, Oliver Langer, Sylvain Auvity, Nicolas Tournier
Format: Article
Language:English
Published: SpringerOpen 2018-08-01
Series:EJNMMI Research
Subjects:
Erlotinib
Solute carrier transporter
Solute carrier O
Organic anion-transporting polypeptide
Liver
Positron emission tomography
Online Access:http://link.springer.com/article/10.1186/s13550-018-0434-0

Internet

http://link.springer.com/article/10.1186/s13550-018-0434-0

Similar Items